Liliana Belgioia1, Isacco Desideri2, Angelo Errico3, Ciro Franzese4, Antonino Daidone5, Lorenza Marino6, Michele Fiore7, Paolo Borghetti8, Daniela Greto2, Alba Fiorentino9. 1. Health Science Department (DISSAL) - University of Genoa and Radiation Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. 2. Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", Section of Radiation Oncology, University of Florence, Italy. 3. Radiation Oncology Department, Mons. R. Dimiccoli Hospital - ASL BT, Barletta, Italy. 4. Department of Radiotherapy and Radiosurgery Istituto Clinico Humanitas "Humanitas Cancer Center", Rozzano, Italy. 5. U.O Radioterapia Oncologica, Ospedale A. Ajello, Mazara del Vallo, Trapani - Radioterapia Oncologica, Centro di Medicina Nucleare, San Gaetano, Bagheria, Palermo, Italy. 6. Rem Radioterapia Viagrande Catania, Italy. 7. Radiation Oncology, Campus Bio-Medico University, Rome, Italy. 8. Radiation Oncology Department University and Spedali Civili, Brescia, Italy. 9. Radiation Oncology Department, General Regional Hospital "F. Miulli", Acquaviva delle fonti, BA, Italy. Electronic address: a.fiorentino@miulli.it.
Abstract
PURPOSE: Aim of the present review is to assess present data about the use of the association of Radiotherapy (RT) and targeted therapy/immunotherapy (TT/IT) in elderly people. DESIGN: PubMed database was searched for English literature published up to December 2017 using the keywords "radiotherapy" combined with "bevacizumab", "cetuximab", "trastuzumab", "erlotinib", "gefitinib", "sorafenib", "sunitinib", "vismodegib", "sonidegib", "ipilimumab", "pembrolizumab", "nivolumab". Studies performing RT and TT/IT in people aged >65-years were evaluated focusing on safety, toxicity and efficacy. Studies eligible for inclusion were: case reports, retrospective/prospective studies in which RT and new drugs were used concomitantly or sequentially, focusing on elderly sub-group. RESULTS: The systematic search identified 626 records. After exclusion of duplicates, full-text review, cross-referencing and paper that did not respect the inclusion criteria, 81 studies were included in this review. In elderly patients the combination of RT with cetuximab or bevacizumab seems feasible but with higher reported side effects. Patients' age should not limit the association of trastuzumab and RT in HER2 positive breast cancer. The concurrent administration of TKIs and RT appears to be feasible and effective. Regarding the Immune Check Point inhibitors and RT, tolerance seems similar among older and younger people but definitive data are lacking. Instead, the association of RT and vismodegib/sonidegib remains investigational. CONCLUSION: TT/IT in association of RT seems to be safe, but in elderly patients data concerning safety and toxicity are limited. Specific clinical trials on this population are encouraged.
PURPOSE: Aim of the present review is to assess present data about the use of the association of Radiotherapy (RT) and targeted therapy/immunotherapy (TT/IT) in elderly people. DESIGN: PubMed database was searched for English literature published up to December 2017 using the keywords "radiotherapy" combined with "bevacizumab", "cetuximab", "trastuzumab", "erlotinib", "gefitinib", "sorafenib", "sunitinib", "vismodegib", "sonidegib", "ipilimumab", "pembrolizumab", "nivolumab". Studies performing RT and TT/IT in people aged >65-years were evaluated focusing on safety, toxicity and efficacy. Studies eligible for inclusion were: case reports, retrospective/prospective studies in which RT and new drugs were used concomitantly or sequentially, focusing on elderly sub-group. RESULTS: The systematic search identified 626 records. After exclusion of duplicates, full-text review, cross-referencing and paper that did not respect the inclusion criteria, 81 studies were included in this review. In elderly patients the combination of RT with cetuximab or bevacizumab seems feasible but with higher reported side effects. Patients' age should not limit the association of trastuzumab and RT in HER2 positive breast cancer. The concurrent administration of TKIs and RT appears to be feasible and effective. Regarding the Immune Check Point inhibitors and RT, tolerance seems similar among older and younger people but definitive data are lacking. Instead, the association of RT and vismodegib/sonidegib remains investigational. CONCLUSION: TT/IT in association of RT seems to be safe, but in elderly patients data concerning safety and toxicity are limited. Specific clinical trials on this population are encouraged.
Authors: Wei Wu; Jessica L Klockow; Suchismita Mohanty; Kimberly S Ku; Maryam Aghighi; Stavros Melemenidis; Zixin Chen; Kai Li; Goreti Ribeiro Morais; Ning Zhao; Jürgen Schlegel; Edward E Graves; Jianghong Rao; Paul M Loadman; Robert A Falconer; Sudip Mukherjee; Frederick T Chin; Heike E Daldrup-Link Journal: Nanotheranostics Date: 2019-09-17
Authors: Evert S M van Aken; Yvette M van der Linden; Johannes V van Thienen; Adrianus J de Langen; Corrie A M Marijnen; Monique C de Jong Journal: Clin Transl Radiat Oncol Date: 2022-01-28
Authors: Geriletu Ao; Maria de Miguel; Ana Gomes; Runhan Liu; Valentina Boni; Irene Moreno; José Miguel Cárdenas; Antonio Cubillo; Lisardo Ugidos; Emiliano Calvo Journal: Invest New Drugs Date: 2021-07-21 Impact factor: 3.850